All In Biotech

Drug Trial Radar · NCT03321955

Ziconotide as First-Line IDT

Prospective Study of Conservative Ziconotide Dosing as a First-Line Intrathecal Drug Therapy for Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Jan 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Nov 3, 2016

Primary completion

Aug 30, 2020

Study completion Dec 30, 2020

Sponsor

Lead sponsor
Albany Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to prospectively examine outcomes in 12 patients using ziconotide Intrathecal Drug Therapy(IDT) as first-line monotherapy with the use of an algorithm of slow titration for dosing. The use of Prialt has demonstrated fewer and less serious associated adverse effects as compared to IDT morphine, especially when titrated slowly. We will use an average Numerical Rating Scale as our primary outcome and the Oswestry Disability Index(ODI), Beck Depression Inventory (BDI), Pain Catastrophizing Scale (PCS), Clinical Global Impression of Change Scale including binary satisfaction measures(CGIC), Lawton-Brody Instrumental Activities of Daily Living(IADL) and Short Form-36 as secondary outcome measures.

Conditions

  • Neuropathic Pain

Interventions

  • Ziconotide 100 MCG(microgram)/ML Intrathecal SolutionDrug

    Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.

  • Quantitative sensory testingDiagnostic test

    Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,

  • Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factorDiagnostic test

    Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numerical Rating Scale (NRS)Time frame: Baseline, 3, 4, 6, 8, 9, 10, 12 week and 4, 5, 6 and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Albany Medical College

    Albany, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.